IP Library › Granted Patent US 12,310,992
Granted Patent B2
US 12,310,992 · App. 18/535,745 · Granted May 27, 2025

Treatment of pulmonary arterial hypertension with prostacyclin-treated endothelial progenitor cells

Inventors: Roger Jeffs (Chapel Hill, NC); Thomas Petersen (Durham, NC); Roger M. Ilagan (Burlington, NC); Michael Wade (Chapel Hill, NC)
Assignee: United Therapeutics Corporation
A61K35/44A61K31/5585A61K35/02A61K35/28A61K45/06C12N5/0692C12N2501/999F04C2270/041
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,310,992
App. No.
18/535,745
Granted
May 27, 2025
Kind
B2
Abstract

The current application is directed to a method for treating pulmonary arterial hypertension (PAH), comprising: providing isolated endothelial progenitor cells (EPCs); treating the EPCs with prostacyclin, wherein the treated EPCs exhibit a hyperproliferative phenotype with enhanced angiogenic property; and administering a composition comprising the treated EPCs into a subject suffering from PAH.

Claims (15)

1. A method for treatment pulmonary hypertension, comprising administering to a subject suffering from pulmonary hypertension (i) a first prostacyclin and (ii) microvesicles obtained from mesenchymal stem cells (MSCs) contacted with a second prostacyclin prior to administration.

2. The method of claim 1 , wherein the first and second prostacyclin are the same prostacyclin.

3. The method of claim 1 , wherein the first or second prostacyclin is treprostinil.

4. The method of claim 1 , wherein the first prostacyclin and microvesicles are co-administered.

5. The method of claim 1 , wherein the first prostacyclin is administered before the microvesicles are administered.

6. The method of claim 1 , wherein the first prostacyclin is administered after the microvesicles are administered.

7. The method of claim 1 , wherein the microvesicles are isolated from a culture medium comprising the MSCs.

8. The method of claim 1 , further comprising administering to the subject the MSCs.

9. The method of claim 1 , further comprising administering to the subject endothelial progenitor cells (EPCs).

10. The method of claim 1 , wherein the patient is suffering from pulmonary arterial hypertension.

11. A method for treating pulmonary arterial hypertension comprising:

(a) providing isolated endothelial progenitor cells (EPCs);

(b) treating the isolated EPCs in vitro or ex vivo with a prostacyclin during expansion of the EPCs, wherein the treated EPCs exhibit a hyperproliferative phenotype with enhanced angiogenic activity; and

(c) administering a composition comprising the treated EPCs to a human subject suffering from pulmonary hypertension.

12. The method of claim 11 , wherein the EPCs are isolated from a human being, a tissue, or cell culture.

Continuity (6)
Division 17072430 · Oct 16, 2020
Continuation 16002250 · Jun 7, 2018
Division 14418557
Provisional Application 61750458 · Jan 9, 2013
Provisional Application 61678208 · Aug 1, 2012
Related Publication 20240131078A1 · Apr 25, 2024
References Cited (130)
US 3089815A · Lieb et al. · 1963 [cited by applicant]
US 4352883A · Lim · 1982 [cited by applicant]
US 4353888A · Sefton · 1982 [cited by applicant]
US 4714680A · Civin · 1987 [cited by applicant]
US 4965204A · Civin · 1990 [cited by applicant]
US 4968733A · Mueller et al. · 1990 [cited by applicant]
US 4976859A · Wechs · 1990 [cited by applicant]
US 4983393A · Cohen et al. · 1991 [cited by applicant]
US 5026365A · Rossini et al. · 1991 [cited by applicant]
US 5035994A · Civin · 1991 [cited by applicant]
US 5071741A · Brockbank · 1991 [cited by applicant]
US 5084350A · Chang et al. · 1992 [cited by applicant]
US 5130144A · Civin · 1992 [cited by applicant]
US 5137809A · Loken et al. · 1992 [cited by applicant]
US 5158881A · Aebischer et al. · 1992 [cited by applicant]
US 5284761A · Aebischer et al. · 1994 [cited by applicant]
US 5643192A · Hirsh et al. · 1997 [cited by applicant]
US 5651982A · Marx · 1997 [cited by applicant]
US 5691176A · Lebkowski et al. · 1997 [cited by applicant]
US 5693531A · Chiorini et al. · 1997 [cited by applicant]
US 5750397A · Tsukamoto et al. · 1998 [cited by applicant]
US 5800828A · Dionne et al. · 1998 [cited by applicant]
US 5811094A · Caplan et al. · 1998 [cited by applicant]
US 6387369B1 · Pittenger et al. · 2002 [cited by applicant]
US 6468527B2 · Austin et al. · 2002 [cited by applicant]
US 7638128B2 · Dzau et al. · 2009 [cited by applicant]
US 10016463B2 · Jeffs · 2018 [cited by examiner]
US 10080730B2 · Jeffs · 2018 [cited by examiner]
US 10842823B2 · Jeffs · 2020 [cited by examiner]
US 11141393B2 · Jeffs · 2021 [cited by examiner]
US 11839631B2 · Jeffs · 2023 [cited by examiner]
US 20030118567A1 · Stewart · 2003 [cited by applicant]
US 20050165111A1 · Wade et al. · 2005 [cited by applicant]
US 20070065414A1 · Freyman et al. · 2007 [cited by applicant]
US 20080050349A1 · Stewart · 2008 [cited by applicant]
US 20080226595A1 · Edinger et al. · 2008 [cited by applicant]
US 20090177262A1 · Oberti et al. · 2009 [cited by applicant]
US 20090274665A1 · Akabutu et al. · 2009 [cited by applicant]
US 20100040584A1 · Melero-Martin et al. · 2010 [cited by applicant]
US 20110003008A1 · Lim · 2011 [cited by applicant]
US 20120172970A1 · Cottone, Jr. et al. · 2012 [cited by applicant]
US 20140193379A1 · Jeffs et al. · 2014 [cited by applicant]
US 20140234278A1 · Heffner · 2014 [cited by applicant]
US 20150246078A1 · Jeffs et al. · 2015 [cited by applicant]
US 20180110807A1 · Ilagan et al. · 2018 [cited by applicant]
WO WO9204033A1 · 1992 [cited by applicant]
WO WO9219195A1 · 1992 [cited by applicant]
WO WO9314191A1 · 1993 [cited by applicant]
WO WO9429438A1 · 1994 [cited by applicant]
WO WO9505452A1 · 1995 [cited by applicant]
WO WO9507611A1 · 1995 [cited by applicant]
WO WO9527071A1 · 1995 [cited by applicant]
WO WO9627287A1 · 1996 [cited by applicant]
WO WO9629862A1 · 1996 [cited by applicant]
WO WO9721824A1 · 1997 [cited by applicant]
WO WO9721825A1 · 1997 [cited by applicant]
WO WO9814058A1 · 1998 [cited by applicant]
WO WO2000024897A1 · 2000 [cited by applicant]
WO WO0104268A1 · 2001 [cited by applicant]
WO WO2004050180A2 · 2004 [cited by applicant]
WO WO2004084921A1 · 2004 [cited by applicant]
WO WO2004085630A1 · 2004 [cited by applicant]
WO WO2006032092A1 · 2006 [cited by applicant]
WO WO2009057313A1 · 2009 [cited by applicant]
WO WO2012027740A1 · 2012 [cited by applicant]
“Second European Consensus Document on Chronic Critical Leg Ischemia”, Circulation, Nov. 1991, 84(4 Suppl.):IV-1-IV-26. [cited by applicant]
Abisambra et al., “Abstracts for the 19 [cited by applicant]
Actelion Pharmaceuticals, “VELETRI: epoprostenol,” prescribing information, 2011, 4 pages. [cited by applicant]
Aizman et al., “Extracellular Matrix Produced by Bone Marrow Stromal Cells and by Their Derivative, SB623 Cells, Supports Neural Cell Growth,” Journal of Neuroscience Research, 2009, 87:3198-3206. [cited by applicant]
Allen et al., “Type I collagen, fibrin and PuraMatrix matrices provide permissive environments for human endothelial and mesenchymal progenitor cells to form neovascular networks,” Journal of Tissue Engineering and Rege… [cited by applicant]
Asahara et al., “Isolation of Putative Progenitor Endothelial Cells for Angiogenesis,” Science, Feb. 17, 1997, 275:964-967. [cited by applicant]
Assmus et al., “Transplantation of Progenitor Cells and Regeneration Enhancement in Acute Myocardial Infarction (TOPCARE-AMI),” Circulation, Nov. 11, 2002, 106:3009-3017. [cited by applicant]
Barst, Robyn MD, FACC, “Is it Possible to Reverse the Endothelial Dysfunction in Pulmonary Arterial Hypertension?”, Journal of the American College of Cardiology, 2007, 49(14):1572-1574. [cited by applicant]
Bregni et al., “Human Peripheral Blood Hematopoietic Progenitors Are Optimal Targets of Retroviral-Mediated Gene Transfer,” Blood, Sep. 15, 1992, 80(6):1418-1422. [cited by applicant]
Chen et al., “Effect on Left Ventricular Function of Intracoronary Transplantation of Autologous Bone Marrow Mesenchymal Stem Cell in Patients with Acute Myocardial Infarction,” The American Journal of Cardiology, Jul. … [cited by applicant]
Clinical All-Round, Nov. 2009, 58(11):2324-2337. [cited by applicant]
Coffin et al., Eds. “Retroviruses”, Chapter 9 pp. 437-473, Cold Springs Harbor Laboratory Press, 1997. [cited by applicant]
D'Alonzo et al., “Survival in Patients with Primary Pulmonary Hypertension,” Ann. Intern. Med., Sep. 1, 1991, 115(5):343-349. [cited by applicant]
Das et al., “The Role of Hypoxia in Bone Marrow-Derived Mesenchymal Stem Cells: Considerations for Regenerative Medicine Approaches,” Tissue Engineering: Part B, Apr. 1, 2010, 16(2):159-168. [cited by applicant]
Di Stefano et al., “The prostacyclin analogue iloprost increases circulating endothelial progenitor cells in patients with critical limb ischemia,” Thrombosis and Haemostasis, Oct. 13, 2008, 100(5):871-877. [cited by applicant]
Doyle et al., “Endothelial Progenitor Cells,” Endothelium, 2006, 13(6):403-410. [cited by applicant]
Eells et al., “Advances in Prostacyclin Therapy for Pulmonary Arterial Hypertension,” Critical Care Nurse, Apr. 2004, 24(2):42-54. [cited by applicant]
Eneroth et al., “Amputation for occlusive arterial disease, A prospective multicentre study of 177 amputees,” Int. Orthop. (SICOT), 1992, 16:383-387. [cited by applicant]
Flamme et al., “Induction of vasculogenesis and hematopoiesis in vitro,” Development, 1992, 116(2):435-439. [cited by applicant]
Grant et al., “Iloprost: A Review of its Pharmacodynamic and Pharmacokinetic Properties, and Therapeutic Potential in Peripheral Vascular Disease, Myocardial Ischaemia and Extracorporeal Circulation Procedures,” Drugs, … [cited by applicant]
Gruber, Scott A., “The Case for Local Immunosuppression,” Transplantation, Jul. 1992, 54:1-11. [cited by applicant]
Hall et al., “Endothelin receptor expression in idiopathic pulmonary arterial hypertension: effect of bosentan and epoprostenol treatment,” Eur. Respir. J., 2011, 38:851-860. [cited by applicant]
Hatzopoulos et al., “Isolation and characterization of endothelial progenitor cells from mouse embryos,” Development, 1998, 125(8):1457-1468. [cited by applicant]
He et al., “Angiogenic function of prostacyclin biosynthesis in human endothelial progenitor cells,” Circulation Research, Jul. 3, 2008, 103(1):80-88. [cited by applicant]
Hill et al, “Circulating Endothelial Progenitor Cells, Vascular Function, and Cardiovascular Risk,” N. Engl. J. Med., 2003, 348:593-600. [cited by applicant]
Hu et al., “Exosomal miRNAs: biological properties and therapeutic potential,” Frontiers in Genetics, Apr. 20, 2012, 3(56):1-9. [cited by applicant]
Humbert et al., “Cellular and Molecular Pathobiology of Pulmonary Arterial Hypertension,” J. Am. Coll. Cardiol., 2004, 43(12:SuppIS):13S-24S. [cited by applicant]
Ingram et al., “Identification of a novel hierarchy of endothelial progenitor cells using human peripheral and umbilical cord blood,” Blood, Jun. 29, 2004, 104:2752-2760. [cited by applicant]
Ishii et al., “Mesenchymal stem cell-based gene therapy with prostacyclin synthase enhanced neovascularization in hindlimb ischemia,” Atherosclerosis, 2009, 206:109-118. [cited by applicant]
Isner et al., “Angiogenesis and vasculogenesis as therapeutic strategies for postnatal neovascularization,” J. Clin. Invest., May 1999, 103(9):1231-1236. [cited by applicant]
Kalka et al., “Transplantation of ex vivo expanded endothelial progenitor cells for therapeutic neovascularization,” P.N.A.S., Mar. 29, 2000, 97(7):3422-3427. [cited by applicant]
Kamio et al., “Prostacyclin analogs stimulate VEGF production from human lung fibroblasts in culture,” Am. J. Physiol. Lung Cell. Mol. Physiol., 2008, 294:L1226-L1232. [cited by applicant]
Karlsson et al., “Nucleation and Growth of Ice Crystals Inside Cultured Hepatocytes During Freezing in the Presence of Dimethyl Sulfoxide,” Biophysical J., Dec. 1993, 65:2524-2536. [cited by applicant]
Kawabe et al., “Role of Autocrine Prostacyclin System in Crucial Functions of Endothelial Progenitor Cells,” Circ. J., 2008, 72(Suppl.1):503, PE-570. [cited by applicant]
Kawabe, Junichi, “Q&A about Thrombosis (Part 6): Please explain prostacyclin and revascularization,” Thrombosis and Circulation, 2011, 19(1):189-191. [cited by applicant]
Keeley et al., “Fibrocytes: Bringing new insights into mechanisms of inflammation and fibrosis,” Int. J. Biochem. Cell Biol., 2010, 42:535-542. [cited by applicant]
Lai et al., “Exosome secreted by MSC reduces myocardial ischemia/reperfusion injury,” Stem Cell Research, 2010, 4(3):214-222. [cited by applicant]
Lai et al., “Mesenchymal stem cell exosome: a novel stem cell-based therapy for cardiovascular disease,” Regen. Med., 2011, 6(4):481-492. [cited by applicant]
Lau et al., “Stem Cells and Regenerative Medicine in Lung Biology and Diseases,” Molecular Therapy, Mar. 6, 2012, 20(6):1116-1130. [cited by applicant]
Lee et al., “Exosomes Mediate the Cytoprotective Action of Mesenchymal Stromal Cells on Hypoxia-Induced Pulmonary Hypertension,” Circulation, Oct. 31, 2012, 126(22):2601-2611. [cited by applicant]
Liu et al., “Engineered Endothelial Progenitor Cells That Overexpress Prostacyclin Protect Vascular Cells,” Journal of Cellular Physiology, Mar. 20, 2012, 227(7):2907-2916. [cited by applicant]
Mayer et al., “Vascular Endothelial Growth Factor (VEGF-A) Expression in Human Mesenchymal Stem Cells: Autocrine and Paracrine Role on Osteoblastic and Endothelial Differentiation,” Journal of Cellular Biochemistry, Jul… [cited by applicant]
Murohara et al., “Transplanted cord blood-derived endothelial precursor cells augment postnatal neovascularization,” J. Clin. Invest., Jun. 2000, 105(11):1527-1536. [cited by applicant]
Nagaya et al., “Hybrid Cell-Gene Therapy for Pulmonary Hypertension Based on Phagocytosing Action of Endothelial Progenitor Cells,” Circulation, Jun. 30, 2003, 108:889-895. [cited by applicant]
Ribatti, Domenico, “The discovery of endothelial progenitor cells, An historical review,” Leukemia Research, 2007, 31:439-444. [cited by applicant]
Risau et al., “Vasculogenesis and angiogenesis in embryonic-stem-cell-derived embryoid bodies,” Development, 1988, 102(3):471-478. [cited by applicant]
Risau, Werner, “Differentiation of endothelium,” FASEB J., 1995, 9(10):926-933. [cited by applicant]
Risau, Werner, “Mechanisms of angiogenesis,” Nature, Apr. 17, 1997, 386(6626): 671-674. [cited by applicant]
Rissanen et al., “Gene therapy for therapeutic angiogenesis in critically ischaemic lower limb—on the way to the clinic,” European Journal of Clinical Investigation, 2001, 31:651-666. [cited by applicant]
Ruan et al., “Prostacyclin Therapy for Pulmonary Arterial Hypertension,” Texas Heart Institute Journal, 2010, 37(4):391-399. [cited by applicant]
Sahara, Makoto, Clinic All-Round, 2009, 58(11):2324-2336, with English translation of indicated relevant portions. [cited by applicant]
Shantsila et al., “Endothelial Progenitor Cells in Cardiovascular Disorders,” Journal of the American College of Cardiology, 2007, 49(7):741-752. [cited by applicant]
Shintani, Satoshi, Heart View, 2011, 15(8):90-96, with English translation of indicated relevant portions. [cited by applicant]
Smadja et al., “Treprostinil increases the number and angiogenic potential of endothelial progenitor cells in children with pulmonary hypertension,” Angiogenesis, 2011, 14(1):17-27. [cited by applicant]
Smithies et al., “Insertion of DNA sequences into the human chromosomal Beta-globin locus by homologous recombination,” Nature, Sep. 19, 1985, 317:230-234. [cited by applicant]
Takahashi et al., “Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization,” Nature Medicine, Apr. 1999, 5(4):434-438. [cited by applicant]
Topol et al., “Combined Tissue-Type Plasminogen Activator and Prostacyclin Therapy for Acute Myocardial Infarction,” J. Am. Coll. Cardiol., 1989, 14(4):877-884. [cited by applicant]
Tyrrell et al., “Critical leg ischaemia: an appraisal of clinical definitions,” Br. J. Surg., Feb. 1003, 80:177-180. [cited by applicant]
Umar et al., “Novel Approaches to Treat Experimental Pulmonary Arterial Hypertension: A Review,” Journal of Biomedicine and Biotechnology, Jan. 1, 2010, 8(1):1-11, Article ID 702836. [cited by applicant]
Wang et al., “Transplantation of Autologous Endothelial Progenitor Cells May Be Beneficial in Patients With Idiopathic Pulmonary Arterial Hypertension,” J. Am. Coll. Cardiol., 2007, 49(14):1566-1571. [cited by applicant]
Williams et al., “Mesenchymal Stem Cells: Biology, Pathophysiology, Translational Findings, and Therapeutic Implications for Cardiac Disease,” Circ. Res., 2011, 109:923-940. [cited by applicant]
Yoder et al., “Redefining endothelial progenitor cells via clonal analysis and hematopoietic stem/progenitor cell principals,” Blood, 2007, 109:1801-1809. [cited by applicant]
Zhao et al., “Rescue of Monocrotaline-Induced Pulmonary Arterial Hypertension Using Bone Marrow- Derived Endothelial-Like Progenitor Cells,” Circ. Res., 2006, 96:442-450. [cited by applicant]
Zhen et al., “Mesenchymal stem cell transplantation increases expression of vascular endothelial growth factor in papain-induced emphysematous lungs and inhibits apoptosis of lung cells,” Cytotherapy, Sep. 1, 2010, 12(5… [cited by applicant]
Zheng et al., “Fidelity of targeted recombination in human fibroblasts and murine embryonic stem cells,” Proc. Natl. Acad. Sci. USA, Sep. 1991, 88:8067-8071. [cited by applicant]